New Brunswick, New Jersey–based J&J unveiled the new stapler midway through last year. Notably, the technology could aid in the future use of the medtech giant’s highly anticipated Ottava surgical robot. Ottava remains investigational globally, with CE mark and FDA de novo approval pending.

The company designed its latest stapler to manage tissue complexities and deliver exceptional staple line integrity. It aims to minimize risk factors for surgical leaks and bleeding complications across specialties. Approval covers open and laparoscopic surgery across the European Union.